RAPT RAPT Therapeutics

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 a.m. Pacific Time.

To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at .

About RAPT Therapeutics, Inc.

RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with inflammatory and immunological diseases. The company leverages its proprietary discovery and development platform to advance both biologics and selective small molecules aimed at normalizing critical immune drivers underlying these conditions.

RAPT Investor Contact:

Sylvia Wheeler

RAPT Media Contact:

Aljanae Reynolds



EN
09/01/2025

Underlying

RAPTRAPT Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RAPT Therapeutics

 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Names Two Industry Veterans to its Board of Director...

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appoint...

June 23, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock S...

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. Following the reverse stock split, the Company’s com...

June 13, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics to Participate in Upcoming Investor Conferences

RAPT Therapeutics to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in June: Goldman Sachs 46th Annual Global Healthcare Conference – Fireside chat on Tuesday, June 10, 2025 at 9:20 a....

June 4, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Reports First Quarter 2025 Financial Results

RAPT Therapeutics Reports First Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the first quarter ended March 31, 2025. “The year is off to a great start. We believe RPT904 has the potential to be a best-in-class option to treat patients with food a...

May 8, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointm...

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a n...

April 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch